Xgeva Approved to Prevent Fractures in Bone Cancer Patients

Links shared publicly online about this topic.

  • 715
    total visits

Xgeva Approved to Prevent Fractures in Bone Cancer Patients

everydayhealth.com

Blocks protein that destroys bone cells

View full resource at everydayhealth.com

Tags: Emergency, Fracture, E coli, Cancer, Bone Cancer, Bone, Protein

  • Share

Most Recently Shared on November 19, 2010 at 8:05 pm By:

EverydayHealth Everyday Health

Xgeva approved to prevent fractures in bone #cancer patients http://ow.ly/3cGB5

1 year ago...

FDA Okays First RANKL Bone-Strength Drug - QualityPoint Technologies

qualitypointtech.net — “WASHINGTON (MedPage Today) -- The FDA has approved the receptor activator of nuclear factor kB Ligand (RANKL) inhibitor denosumab (Xgeva) for the prevention of weakened bones and other skeletal-related events in patients with bone cancer from solid tumors.View full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on November 20, 2010 at 12:02 am By:

MedicalFeed MedicalFeed Health News Feed

FDA Okays First RANKL Bone-Strength Drug: WASHINGTON (MedPage Today) -- The FDA has approved the receptor activato... http://bit.ly/cbDVQu

1 year ago...

Xgeva Approved to Prevent Fractures in Bone Cancer Patients - Drugs.com MedNews

drugs.com — “Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to prevent fractures and other skeletal complications in people with advanced canceView full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on November 19, 2010 at 6:10 pm By:

Drugs_Devices Drugs and Devices OW OW Health

Xgeva Approved to Prevent Fractures in Bone Cancer Patients: FRIDAY, Nov. 19 -- Xgeva (denosumab) has been... http://bit.ly/8YfC8q #drug

1 year ago...

Xgeva approved for prevention of skeletal-related events in cancer patients - MPR

empr.com — “Amgen announced that the FDA has approved Xgeva (denosumab), a RANK (Receptor Activator for Nuclear Factor B) ligand inhibitor, for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.View full resource at empr.com

  • View Related
  • Share

Most Recently Shared on November 19, 2010 at 4:54 pm By:

eMPR MPR Medical Publisher

MPR News: Xgeva approved for prevention of skeletal-related events in cancer patients: Amgen announced that the ... http://bit.ly/9T1xfA

1 year ago...

Advertisement